222 related articles for article (PubMed ID: 24093937)
21. The impact of EpCAM expression on response to chemotherapy and clinical outcomes in patients with epithelial ovarian cancer.
Tayama S; Motohara T; Narantuya D; Li C; Fujimoto K; Sakaguchi I; Tashiro H; Saya H; Nagano O; Katabuchi H
Oncotarget; 2017 Jul; 8(27):44312-44325. PubMed ID: 28574829
[TBL] [Abstract][Full Text] [Related]
22. Oligonucleotide modulation of multidrug resistance.
Bouffard DY; Ohkawa T; Kijima H; Irie A; Suzuki T; Curcio LD; Holm PS; Sassani A; Scanlon KJ
Eur J Cancer; 1996 Jun; 32A(6):1010-8. PubMed ID: 8763342
[No Abstract] [Full Text] [Related]
23. Expression of FOXP1 in epithelial ovarian cancer (EOC) and its correlation with chemotherapy resistance and prognosis.
Hu Z; Zhu L; Gao J; Cai M; Tan M; Liu J; Lin B
Tumour Biol; 2015 Sep; 36(9):7269-75. PubMed ID: 25895457
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of biomarkers related to drug resistance in patients with advanced epithelial ovarian cancer.
Kim H; Kim K; No JH; Jeon YT; Jeon HW; Kim YB
Anticancer Res; 2012 Feb; 32(2):589-94. PubMed ID: 22287749
[TBL] [Abstract][Full Text] [Related]
25. Therapy-related myeloid neoplasms in epithelial ovarian cancer patients carrying BRCA1 mutation: report of two cases.
Melichar B; Laco J; Fridrichová P; Simkovič M; Papajík T; Foretová L
Acta Oncol; 2012 Jan; 51(1):136-8. PubMed ID: 21859355
[No Abstract] [Full Text] [Related]
26. Unanswered questions about multidrug resistance.
Beck WT
Cytotechnology; 1996; 19(3):177-9. PubMed ID: 8862003
[No Abstract] [Full Text] [Related]
27. Expression of PKCα, PKCε, and P-gp in epithelial ovarian carcinoma and the clinical significance.
Lili X; Xiaoyu T
Eur J Gynaecol Oncol; 2015; 36(2):181-5. PubMed ID: 26050357
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of pregnane X receptor pathway contributes to the cell growth inhibition and apoptosis of anticancer agents in ovarian cancer cells.
Masuyama H; Nakamura K; Nobumoto E; Hiramatsu Y
Int J Oncol; 2016 Sep; 49(3):1211-20. PubMed ID: 27572875
[TBL] [Abstract][Full Text] [Related]
29. Panitumumab and pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer with KRAS wild-type: the PaLiDo study, a phase II nonrandomized multicenter study.
Steffensen KD; Waldstrøm M; Pallisgård N; Lund B; Bergfeldt K; Wihl J; Keldsen N; Marth C; Vergote I; Jakobsen A
Int J Gynecol Cancer; 2013 Jan; 23(1):73-80. PubMed ID: 23211422
[TBL] [Abstract][Full Text] [Related]
30. [Molecular mechanisms of chemotherapeutic resistance in genitourinary cancers].
Kakehi Y
Nihon Hinyokika Gakkai Zasshi; 1998 Jan; 89(1):1-13. PubMed ID: 9493416
[No Abstract] [Full Text] [Related]
31. Combining targeted therapies in ovarian cancer.
Scambia G; Salutari V; Ferrandina G
Lancet Oncol; 2014 Oct; 15(11):1179-81. PubMed ID: 25218905
[No Abstract] [Full Text] [Related]
32. The role of P-glycoprotein in drug resistance in multiple myeloma.
Abraham J; Salama NN; Azab AK
Leuk Lymphoma; 2015 Jan; 56(1):26-33. PubMed ID: 24678978
[TBL] [Abstract][Full Text] [Related]
33. Molecular pathways: regulation and therapeutic implications of multidrug resistance.
Chen KG; Sikic BI
Clin Cancer Res; 2012 Apr; 18(7):1863-9. PubMed ID: 22344233
[TBL] [Abstract][Full Text] [Related]
34. Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer.
Marchini S; Fruscio R; Clivio L; Beltrame L; Porcu L; Fuso Nerini I; Cavalieri D; Chiorino G; Cattoretti G; Mangioni C; Milani R; Torri V; Romualdi C; Zambelli A; Romano M; Signorelli M; di Giandomenico S; D'Incalci M
Eur J Cancer; 2013 Jan; 49(2):520-30. PubMed ID: 22897840
[TBL] [Abstract][Full Text] [Related]
35. A dual-fluorescence high-throughput cell line system for probing multidrug resistance.
Brimacombe KR; Hall MD; Auld DS; Inglese J; Austin CP; Gottesman MM; Fung KL
Assay Drug Dev Technol; 2009 Jun; 7(3):233-49. PubMed ID: 19548831
[TBL] [Abstract][Full Text] [Related]
36. Corilagin sensitizes epithelial ovarian cancer to chemotherapy by inhibiting Snail‑glycolysis pathways.
Jia L; Zhou J; Zhao H; Jin H; Lv M; Zhao N; Zheng Z; Lu Y; Ming Y; Yu Y
Oncol Rep; 2017 Oct; 38(4):2464-2470. PubMed ID: 28791374
[TBL] [Abstract][Full Text] [Related]
37. The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer.
Gui T; Shen K
Cancer Epidemiol; 2012 Oct; 36(5):490-6. PubMed ID: 22818908
[TBL] [Abstract][Full Text] [Related]
38. [Effect of evidence-based medicine on the decision of chemotherapy for epithelial ovarian cancer].
Li GT
Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):582-6. PubMed ID: 23141177
[No Abstract] [Full Text] [Related]
39. Controversy in treatment of advanced ovarian cancer.
Scambia G; Salutari V; Amadio G
Lancet Oncol; 2013 Sep; 14(10):920-1. PubMed ID: 23993374
[No Abstract] [Full Text] [Related]
40. MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer.
Pénzváltó Z; Lánczky A; Lénárt J; Meggyesházi N; Krenács T; Szoboszlai N; Denkert C; Pete I; Győrffy B
BMC Cancer; 2014 Nov; 14():837. PubMed ID: 25408231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
